Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Baxter
Harvard Business School
Moodys
Medtronic

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021758

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 021758 describes VANOS, which is a drug marketed by Medicis and is included in one NDA. It is available from two suppliers. There are four patents protecting this drug and one Paragraph IV challenge. Additional details are available on the VANOS profile page.

The generic ingredient in VANOS is fluocinonide. There are nine drug master file entries for this compound. Thirty-nine suppliers are listed for this compound. Additional details are available on the fluocinonide profile page.
Summary for 021758
Tradename:VANOS
Applicant:Medicis
Ingredient:fluocinonide
Patents:4
Formulation / Manufacturing:see details
Pharmacology for NDA: 021758
Medical Subject Heading (MeSH) Categories for 021758
Suppliers and Packaging for NDA: 021758
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VANOS fluocinonide CREAM;TOPICAL 021758 NDA AUTHORIZED GENERIC Oceanside Pharmaceuticals 68682-992 68682-992-10 1 TUBE in 1 CARTON (68682-992-10) > 120 g in 1 TUBE
VANOS fluocinonide CREAM;TOPICAL 021758 NDA AUTHORIZED GENERIC Oceanside Pharmaceuticals 68682-992 68682-992-30 1 TUBE in 1 CARTON (68682-992-30) > 30 g in 1 TUBE
Paragraph IV (Patent) Challenges for 021758
Tradename Dosage Ingredient NDA Submissiondate
VANOS CREAM;TOPICAL fluocinonide 021758 2008-01-31

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CREAM;TOPICALStrength0.1%
Approval Date:Feb 11, 2005TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Dec 21, 2021Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Jan 7, 2023Product Flag?Substance Flag?Delist Request?
Patented Use:RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER
Patent:  Start TrialPatent Expiration:Sep 11, 2022Product Flag?Substance Flag?Delist Request?
Patented Use:RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Colorcon
Johnson and Johnson
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.